

DAFTAR PUSTAKA

- Aberg, J.A., Kaplan, J.E., Libman, H., Emmanuel, P., Anderson, J.R., Stone, V.E., Oleske, J.M., Currier, J.S., Gallant, J.E., 2009. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine association of the infectious diseases society of America. *CID*. 49:651-81.
- AIDSinfo, 2014. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Departement of helath and human services. Available at: <http://aidsinfo.nih.gov/ContentsFiles/AdultandAdolescentGL.pdf>
- Al-Jabri, A.A., 2007. Review: Mechanism of host resistance against HIV infection and progression to AIDS. *Sultan Qaboos University Journal*. 7(2):82-86.
- Anderson, P.L., Kakuda, T.N., Fletcher, C.V., 2008. Human Immunodeficiency Virus. In: *Pharmacotherapy: A pathophysiology approach Ed. 7*, pp: 2065-83. The McGraw-Hill Companies, United States of America.
- Barry, O., Powell, J., Renner, L., Bonney, E.Y., Prin, M., Ampofo, W., Kusah, J., Goka, B., Sagoe, K.W.C., Shabanova, V., Paintsil, E., 2013. Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in Ghana. *BMC Infectious Disease*. 13:476.
- Berg-Wolf, M.V.D., Hullsiek, K.H., Peng, G., Kozal, M.J., Novak, R.M., Chen, L., Crane, L.R., MacArthur, R.D., 2008. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimen as initial therapy in HIV-1-infected persons. *HIV Clin Trials*. 9(5):324-336.
- Bwakura-Dangarembizi, M., Lindsay, K., Bakeera-Kitaka, S., Nahiry-Ntege, P., Keishanyu, R., Nathoo, K., Spyer, M.J., Kekitiinwa, A., Lutaakome, J., Mhutee, A., Kasirye, P., Munderi, P., Mussime, V., Gibb, D.M., Walker, A.S., Prendergast, A.J., 2014. A randomized controlled of prolonged cotrimoxazole in HIV-infected children in Africa. *N Engl J Med*. 370:41-53.
- Cain, L.E., Philips, A., Lodi, S., Sabin, C., Bansil, L., Justice, A., Tate, J., Logan, R., Robin, J.M., Sterner, J.A.C., van Shigen, A., 2012. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. *AIDS*. 26(13): 1691–1705.

- de Castilla, D.L., Verdonck, K., Otero, L., Iglesias, D., Echevarria, J., Lut, L., Gotuzzo, E., Seas, C., 2008. Predictors of CD4⁺ cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru. *International Journal of Infectious Diseases*. 12:325-331.
- Ditjen PP & PL Kemenkes RI, 2011. Pedoman nasional tatalaksana klinis infeksi HIV dan terapi antiretroviral. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Ditjen PP & PL Kemenkes RI, 2014. Laporan statistik kasus HIV/AIDS di Indonesia sampai sepetember 2014. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Eleje, G.U., Ele, P.U., Okocha, E.C., Iloduba, U.C., 2014. Epidemiology and clinical parameters of adult human immunodeficiency virus/acquired immunodeficiency syndrome at the initiation of antiretroviral therapy in South Eastern Nigeria. *Annals of Medical and Health Sciences Research*. 4(2):217-221.
- Gallant, J.E., DeJesus, E., Arribas, J.R., Pozniak, A.L., Gazzard, B., Campo, R.E., Lu, B., McColl, D., Chuck, S., Enejosa, J., Toole, J.J., Cheng, A.K., 2006. Tenofovir DF, Emtricitabine, Efavirenz vs. Zidovudin, Lamivudine, Efavirenz for HIV. *N Engl J Med*. 354:251-60.
- Hile, S.J., Feldman, M.B., Alexy, E.R., Irvine, M.K., 2016. Recent tobacco smoking is associated with poor HIV outcomes among HIV-infected individuals in New York. *AIDS Behav*. 20:1722-1729.
- Hoffman, C.J., Fielding, K.L., Charalambous, S., Sulkowski, M.S., Innes, C., Thio, C.L., Chaisson, R.E., Churchyard, G.J., Grant, A.D., 2008. Antiretroviral therapy using Zidovudin, Lamivudine, and Efavirenz in South Africa: tolerability and clinical events. *AIDS*. 22(1):67-74.
- Htun, W.L., Bowonwatanuwong, C., Phonrat, B., Pitisuttithum, 2012. Long-term outcomes of nevirapine containing antiretroviral therapy at a center in Thailand. *Southeast Asian J Trop Med Public Health*. 43(4): 861-70.
- Hunt, K., Mondal, P., Konrad, S., Skinner, S., Gartner, K., Lim, H.J., 2015. Identifying factors associated with changes CD4⁺ count in HIV-infected adults in Saskatoon, Saskatchewan. *Can J Infect Dis Med Microbiol*. 26(4):207-15.

- Kabali, C., Cheng, D.M., Brooks, D.R., Bridde, C., Horsburgh Jr., C.R., Samet, J.H., 2011. Recent cigarette smoking and HIV disease progression: no evidence of an association. *AIDS Care*. 23(8):947-956.
- Kilaru, K.R., Kumar, A., Sippy, N., Carter, A.O., Roach, T.C., 2006. Immunological dan virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. *HIV Medicine*. 7:99-104.
- Lapphra, K., Vanprapar, N., Cherskul, S., Phongsamart, W., Chearskul, P., Prasitsuebsai, W., Chokephaiibulkit, K., 2008. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children. *International Journal of Infectious Diseases*. 12:e33-e38.
- Le, T., Wright, E.J., Smith, D.M., He, W., Catano, G., Okulicz, J.F., Young, J.A., Clark, R.A., Richman, D.D., Little, S. J., Ahuja, S. K., 2013. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. *N Engl J Med*. 368:218-30.
- Manfredi, R., Calza, L., Chiodo, F., 2004. EFavirenz versus nevirapine in current clinical practice; a prospective, open-label observational study. *J Acquir Immune Defic Syndr*. 35(5):492-502.
- Martinson, N.A., Gupte, N., Msandiwa, R., Moulton, L.H., Barnes, G.L., Ram, M., Gray, G., Hoffman, C., Chaisson, R.E., 2014. CD4 and viral load dynamic in antiretroviral-naïve HIV-infected adults from Soweto, South Africa: a prospective cohort. *PLoS ONE*. 9(5):e96369.
- Mwesigire, D.M., Wu, A.W., Martin, F., Katamba, A., Seeley, 2015. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study. *BMC Health Service Research*. 15:292.
- Nachagea, J.B., Hislop, M., Dowdy, D.W., Gallant, J.E., Chaisson, R.E., Regensberg, L., Maartens, G., 2008. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in southern African adults. *AIDS*. 22(16):2117-2125.
- Olowookere, S.A., Fatiregun, A.A., Ladipo, M.M.A., Abioye-Kuteyi, E.A., Adewole, I.F., 2016. Effects of adherence to antiretroviral therapy on body mass index, immunological dan virological status of Nigerians living with HIV/AIDS. *Alexandria Journal of Medicine*. 52(1):51-4.

- Pandrea, I., Happel, K.I., Amedee, A.M., Bagby, G.J., Nelson, S., 2010. Alcohol's role in HIV transmission and disease progression. *Alcohol Research & Health*. 33(3):203-18.
- Patel, A.K., Pujari, S., Patel, K., Shah, N., Patel, B., Gupte, N., 2006. Nevirapine versus efavirenz based antiretroviral treatment in naïve Indian patients: coparisson of effectiveness in clinical cohort. *JAPI*. 54:915-918.
- Pillay, P., Ford, N., Shubber, Z., Ferrand, R.A., 2013. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of hiv-1 infection: a systematic review and meta-analysis. *PLoS ONE*. 8(7): e68995.
- Rajesh, R., Vidyasagar, S., Naren, P., Varghese, M., 2010. Safety aspects of antiretroviral therapy for management of HIV infection. *J B Clin Pharm*. 1(1):47-53.
- Severe, P., Juste, M.A.J., Ambroise, A., Eliacin, L., Marchand, C., Apollon, S., Edward, A., Bang, H., Nicotera, J., Godfrey, C., Gulick, R.M., Johnson, W.D., Pape, J.W., Fitzgerald, D.W., 2010. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. *N Engl J Med*. 363:257-65.
- Shearer, K., Brennan, A.T., Maskew, M., Long, L., Berhanu, R., Sanne, I., Fox, M. P., The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. *JIAS*. 17:1-10.
- Simon, V., Ho, D.D., Karim, Q.A., 2006. HIV/AIDS epidemiology, pathogenesis, prevention and treatment. *Lancet*. 368:489-504.
- Sinha, A., Raghunandan, P., Chandrashekhar, R., Sharma, S.K., Kumar, S., Dhooria, S., Ekka, M., Velpandian, T., Ranjan, S., Ahmad, H., Samantaray, J.C., Venkatesh, S., Rewari, B.B., Khan, N.H., Pande, R.M., 2013. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naïve patients with HIV and tuberculosis infections in India: a pilot study. *BMC Infectious Diseases*. 13:482.
- Swaminathan, S., Padmapriyadarsini, C., Vankatesan, P., Narendran, G., Kumar, S.R., Iliaya, S., Menan, P.A., Selvaraju, S., Pooranagangadevi, N.P., Bhavani, P.K., Ponnuraja, C., Dilip, M., Ramachandran, 2011. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis; a randomized clinical trial. *Clinical Infectious Diseases*. 53(7):716-724.

- Takuva, S., Evans, D., Zuma, K., Okello, V., Louwagie, G., 2013. Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults. *Pan African Medical Journal*. 15(5):1-5,
- Tirfe, Z.M., Ahmed, T.A., Tedla, N.B., Debere, M.K., Alamdo, A.G., 2013. Immunological responses of HIV/AIDS patients treated with nevirapine versus efavirenz based highly active anti-retroviral therapy in Addis Ababa, Ethiopia: a retrospective study. *Health*. 5 (9): 1502-1508.
- Tozzi V. Review: Pharmacogenetic of antiretroviral. *Antiviral Research* 2010. 85:190–200.
- UNAIDS, 2016. Fact sheet 2016; Global statistic human immunodeficiency virus 2015. The Joint United Nations Programme on HIV/AIDS (UNAIDS).
- Van Leth, F., Andrews, S., Grinsztejn, Wilkins, E., Lazanas, M.K., Lange, J.M.A., Montaner, J., 2005. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. *AIDS*. 19;463-471.
- Van Leth, F., Wit, F.W.N.M., Reiss, P., Schattenkerk, J.K.M.E., Van Der Ende, M.E., Mulder, J.W., Frissen, P.H.J., de Wolf, F., Lange, J.M.A., 2004. Differential CD4 T-Cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy. *HIV Medicine*. 5:74-81.
- Volberding, V.A., Deeks, S.G., 2010. Antiretroviral therapy and management of HIV infection. *Lancet*. 376:49-62.
- Young, S., Wheeler, A.C., McCoy, S.I., Weiser, S.D., 2014. A review of the role of food insecurity in adherence to care and treatment among adult and pediatric populations living with HIV and AIDS. *AIDS Behav*. 18:S505–S515
- Zhang, F., Sun, M., Sun, J., Guan, L., Wang, J., Lu, H., 2015. The risk factors for suboptimal CD4 recovery in HIV infected population: an observational and retrospective study in Shanghai, China. *BioScience Trends*. 9(5):335-341.

